Stocks
Intellia Therapeutics, Inc.NTLA
NASDAQHealthcareBiotechnology$12.76-0.70%
A clinical-stage biotechnology company developing CRISPR-based gene editing therapies designed to treat genetic diseases. Its pipeline focuses on in vivo genome editing programs, including treatments for transthyretin amyloidosis and other rare disorders, with key collaborations such as its partners...
Market Cap: $1.5B52W Range: $5.90 – $28.25
Congressional Interest in Intellia Therapeutics, Inc. (NTLA)
4 members of Congress have disclosed 15 trades in Intellia Therapeutics, Inc. (NTLA), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 8 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
15
Unique Politicians
4
Buys
7
Sells
8
Who in Congress Is Trading NTLA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-08-25 | Thomas R Carper | sell | $1K – $15K |
| 2023-05-22 | Thomas R Carper | buy | $1K – $15K |